Subpoena is latin for love, right?
In any case, Amgen was on the receiving end of
a compelling request from the New York Attorney General's office.
According to a recent SEC filing the May 10th letter sought wide ranging documentation from the pharmaceutical company, including: data on the company's sales and marketing, medical education, clinical studies, pricing, contracting, licensing and distribution agreements as well as corporate communications.
Amgen is
already facing class action litigation filed in the U.S. District Court for the Central District of California. , alleging securities fraud.
-- MDT
Labels: Amgen, class action, New York AG, securities, subpoena